Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline.
Patients with anorexia nervosa have concurrent problems of emaciation and depression. Therefore, treatment with medications affecting both weight gain and depression seemed reasonable. Seventy-two anorectic patients were randomly assigned in a double-blind study to receive cyproheptadine hydrochloride, a weight-inducing drug, amitriptyline hydrochloride, a tricyclic antidepressant, or placebo. Overall, cyproheptadine had a marginal effect on decreasing the number of days necessary to achieve a normal weight. There was a differential drug effect present in the bulimic subgroups of the anorectic patients: cyproheptadine significantly increased treatment efficiency for the nonbulimic patients and significantly impaired treatment efficiency for the bulimic patients when compared with the amitriptyline- and placebo-treated groups. The differential cyproheptadine effect on the anorectic bulimic subgroups is the first pharmacologic evidence of the validity of these subgroups. Cyproheptadine had an anti-depressant effect demonstrated by a significant decrease in the Hamilton depression ratings.
D000293:Adolescent; D000328:Adult; D000639:Amitriptyline / Q000627:therapeutic use*; D000856:Anorexia Nervosa / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003533:Cyproheptadine / Q000494:pharmacology / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology; D004311:Double-Blind Method; D004614:Emaciation / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D006963:Hyperphagia / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D010919:Placebos
D010919:Placebos; D000639:Amitriptyline; D003533:Cyproheptadine